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Mitochondria in epithelial ovarian 
carcinoma exhibit abnormal 
phenotypes and blunted 
associations with biobehavioral 
factors
Snehal Bindra1, Marlon A. McGill1, Marina K. Triplett1, Anisha Tyagi1, Premal H. Thaker2, 
Laila Dahmoush3, Michael J. Goodheart4, R. Todd Ogden5, Edward Owusu‑Ansah6, 
Kalpita R Karan1, Steve Cole7, Anil K. Sood8, Susan K. Lutgendorf4,9,10* & 
Martin Picard1,11,12*
Malignant tumor cells exhibit mitochondrial alterations and are also influenced by biobehavioral 
processes, but the intersection of biobehavioral factors and mitochondria in malignant tumors 
remains unexplored. Here we examined multiple biochemical and molecular markers of mitochondrial 
content and function in benign tissue and in high‑grade epithelial ovarian carcinoma (EOC) in parallel 
with exploratory analyses of biobehavioral factors. First, analysis of a publicly‑available database 
(n = 1435) showed that gene expression of specific mitochondrial proteins in EOC is associated with 
survival. Quantifying multiple biochemical and molecular markers of mitochondrial content and 
function in tissue from 51 patients with benign ovarian masses and 128 patients with high‑grade EOC 
revealed that compared to benign tissue, EOCs exhibit 3.3–8.4‑fold higher mitochondrial content 
and respiratory chain enzymatic activities (P < 0.001) but similar mitochondrial DNA (mtDNA) levels 
(− 3.1%), documenting abnormal mitochondrial phenotypes in EOC. Mitochondrial respiratory chain 
activity was also associated with interleukin‑6 (IL‑6) levels in ascites. In benign tissue, negative 
biobehavioral factors were inversely correlated with mitochondrial content and respiratory 
chain activities, whereas positive biobehavioral factors tended to be positively correlated with 
mitochondrial measures, although effect sizes were small to medium (r = − 0.43 to 0.47). In contrast, 
serous EOCs showed less pronounced biobehavioral‑mitochondrial correlations. These results 
document abnormal mitochondrial functional phenotypes in EOC and warrant further research on the 
link between biobehavioral factors and mitochondria in cancer.
Mitochondria play a pivotal role in the growth of malignant tumors (henceforth “tumor” is used to refer specifi-
cally to malignant tumors). Mitochondrial function enables tumor cell adaptation to stressful environments, 
provides plasticity for tumor growth and survival, confers resistance to apoptotic signaling, and can promote 
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metastatic  phenotypes1–3. Human tumor cells exhibit altered energy metabolism and metabolic reprogramming 
associated with alterations in mitochondrial DNA (mtDNA) and its associated  proteins4. Retrograde signaling 
from mitochondria to the nucleus can also promote a shift in cellular metabolism towards aerobic  glycolysis5. 
Clinically, mitochondrial dysfunction is therefore believed to contribute to tumor  progression6,  chemoresistance7, 
and reduced progression-free survival (PFS)8,9. Ovarian carcinoma cells also secrete pro-inflammatory media-
tors such as interleukin-6 (IL-6) which in turn promote tumor proliferation, invasion, and  chemoresistance10. 
Furthermore, metabolic changes in healthy stromal tissue surrounding the tumor (tumor microenvironment) 
produce metabolites that promote inflammation and support tumor  growth11. Therefore, mitochondrial func-
tion—both within benign and tumor tissues—represents a potential pathway that may influence tumor behavior 
and downstream clinical outcomes.
A substantial body of research over the last 30 years documents relationships between biobehavioral factors 
and cancer progression. Biobehavioral pathways—referring collectively to behavioral, social, and/or psychological 
factors and concomitant biologic processes—can directly affect neuroendocrine signaling pathways to enhance 
tumor growth and impair the immune response in  cancer12. Specifically, psychological stress, beta-adrenergic, 
and glucocorticoid signaling have been shown to enhance processes such as angiogenesis, tumor cell invasion, 
and resistance to anoikis, representing additional pathways that promote tumor growth and  metastasis13,14. 
Biobehavioral factors also have indirect effects on tumors via effects on host cells in the tumor microenvironment 
such as macrophages or fibroblasts that can be repurposed to promote tumor  growth12,15,16. Collectively, these 
data suggest the existence of biological mechanisms to translate positive and negative psychosocial experiences 
into molecular changes within tumors.
Mitochondria have been shown to dynamically respond to biobehavioral processes and to be functionally 
linked to the major neuroendocrine and immune pathways that are known to be modulated by psychological 
 states17–19. This includes glucocorticoid stress hormones released during psychosocial stress and their associated 
metabolic  effects20. A systematic review of the literature revealed consistent effects of chronic mental stress on 
mitochondria including mitochondrial content and the activity of respiratory chain complexes involved in energy 
 transformation21. In mitochondria, both the respiratory chain involved in energy production and macromolecule 
biosynthesis, as well as the maintenance of the mitochondrial genome, can be a target of biobehavioral processes. 
Considering both these genetic and biochemical aspects, we recently developed a high-throughput approach 
to simultaneously monitor i) mitochondrial content and ii) functional capacity in human blood  leukocytes22. 
Using this approach in parallel with daily biobehavioral assessments revealed that mood is associated with mito-
chondrial functional capacity on subsequent  days22. Moreover, acute mental stress that induces negative mood 
can also lead to the release of the potentially immunogenic circulating cell-free mtDNA (cf-mtDNA) in plasma 
and serum within minutes 23,24, providing further evidence that mitochondria in normal (i.e., non-cancerous) 
tissues functionally respond to biobehavioral factors.
Here, to examine the potential relevance of mitochondrial function in ovarian cancer, we first surveyed a 
publicly-available ovarian cancer gene expression dataset. We characterized multiple biochemical and molecular 
markers of mitochondrial content and function in non-cancerous tissue and tissue from ovarian carcinomas, 
in parallel with inflammation. To explore whether mitochondrial remodeling represents a potential pathway by 
which biobehavioral processes may support tumor growth and progression, we also quantified the association 
of biobehavioral factors and mitochondrial phenotypes in epithelial ovarian carcinomas (EOC) or benign tissue.
Results
Mitochondrial gene expression and survival. We first leveraged a publicly available gene expression 
dataset, Kaplan Meier  Plotter25,26, to examine whether ovarian cancer outcomes, such as survival, are associated 
with the expression of mitochondrial genes. Low levels of a major regulator of mitochondrial metabolism, the 
mitochondrial pyruvate carrier (MPC2), are known to promote metabolic reprogramming and are associated 
with greater mortality when MPC is removed in cells and preclinical  models27. Initial analyses included patients 
with different histological subtypes, stages, and grades of EOC. Among 614 women with ovarian cancer cases 
followed over 20 years, we found that relative to those with high MPC2 gene expression, low MPC expression 
was associated with a 59% increase in mortality (p < 0.0001, Fig. 1A), suggesting that mitochondrial metabolism 
contributes to ovarian tumor biology in humans.
We then extended this analysis to genes encoding subunits of the respiratory chain complexes I-V, which are 
involved in mitochondrial oxidative  phosphorylation28. Similar to MPC2, we generated Kaplan–Meier curves 
for each available gene encoding a subunit of respiratory chain complexes I through V. The expression levels 
of respiratory chain subunits, as well as mtDNA maintenance genes, were variably associated with mortality 
(Fig. 1B-G). Compared to a set of randomly selected genes (false discovery rate: 58.5%), the proportion of subu-
nits significantly associated with mortality was higher for complexes II, III and mtDNA-related genes (Fig. 1H). 
Sensitivity analyses restricting data to high grade patients performed on expression of MPC2, complex II, and 
mtDNA-related genes yielded similar results (data not shown). Together, these epidemiological, longitudinal data 
indirectly suggested that ovarian cancer biology in humans may be modulated by metabolic and mitochondrial 
factors.
Mitochondrial phenotyping in ovarian tumors. To examine the link between mitochondrial respira-
tory chain function and ovarian cancer outcomes more directly, we then analyzed tissue from high-grade EOC 
(n = 128) and benign ovarian masses (n = 51) collected during surgery (Fig. 2A). EOCs were histologically identi-
fied as serous, endometrioid, mucinous, or clear cell, with the majority (78.1%) being serous. All tumors were 
high grade. Benign masses were of epithelial and stromal histology.
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To account for possible tumor heterogeneity in the enzymatic and molecular analyses, two partitions of each 
sample were processed in parallel, measured in triplicate, and the average taken to reflect each ovarian sam-
ple most robustly. Our approach included parallel measurements of enzymatic activities for respiratory chain 
complexes II (succinate dehydrogenase, SDH) and IV (cytochrome c oxidase, COX) reflecting mitochondrial 
respiratory chain capacity, as well as citrate synthase (CS) and mtDNA copy number (mtDNAcn) reflecting mito-
chondrial content (Fig. 2B). On average, in EOC the mitochondrial enzymes were moderately correlated with 
each other, sharing 20.3–47.3% of their variance, whereas mtDNAcn was minimally correlated with enzymatic 
activities (1.1–3.4% of shared variance). These data suggest that each mitochondrial marker contributes different 
information about the tumor mitochondrial phenotypes and that mtDNAcn is likely regulated independently 
from enzymatic measures. Age was examined as a possible factor that might influence mitochondrial function. 
Enzymatic activities and mtDNAcn in EOC were minimally associated with age  (r2 = 0.00–0.078), such that < 8% 
of the variation in mitochondrial content and function was attributable to age in this cohort. The results were 

























































































































































































































Figure 1.  Expression of mitochondrial genes predict survival in ovarian cancer patients. (A) Kaplan Meier 
Plotter (KMPlot.org) survival analysis of patients with ovarian cancer exhibiting low (n = 454) or high (n = 160) 
gene expression for a key component of mitochondrial metabolism, the mitochondrial pyruvate carrier 2 
(MPC2) gene. (B) Hazard ratios (HR) from Kaplan Meier survival analysis shown as forest plots for genes 
encoding subunits of the mitochondrial respiratory chain complexes I, (C) II, (D) III, (E) IV, (F) V, and (G) and 
mtDNA-related genes. (H) Summary of results illustrating the proportion of significant subunits in previous 
analysis relative to results from a randomly selected group of 200 genes. Shown are mean HR with 95% C.I. 
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Mitochondrial content and function are elevated in EOC relative to benign. We first compared 
mitochondrial measures between high-grade EOC tissue and benign ovarian masses. Relative to benign tissue, 
ovarian tumors exhibited a striking 8.4-fold higher CS activity, 3.3-fold higher SDH activity, and a 8.2-fold 
higher COX activity (Fig. 2C), but a similar (3.1% lower, N.S.) mtDNAcn (Fig. 2D). The mitochondrial health 
index (MHI), a computed metric representing the ratio of respiratory chain activity (SDH and COX) divided 
by markers of mitochondrial content (CS and mtDNAcn)22, was also double in EOC compared to benign tissue 
(Fig. 2E). Because SDH is uniquely encoded in the nuclear genome, whereas COX is partially mtDNA-encoded, 
we also computed the ratio of both enzymes (Fig.  2F), which can be indicative of abnormal mitochondrial 
 phenotypes29. Here the COX/SDH ratio was approximately 3 times higher in EOC. Plotting each tumor and 
benign sample in a bi-plot showed fairly good separation between both groups, indicating a possible imbalance 
or recalibration of the respiratory chain components in tumor tissue (Fig. 2G). Moreover, the minimal decline in 
mtDNAcn in light of the approximately 3.3–8.4-fold higher mitochondrial mass means that the mitochondrial 
Figure 2.  Mitochondrial profiling in benign and epithelial ovarian carcinoma (EOC) tissue. (A) Overview 
of the study design illustrating the multi-level approach ranging from biobehavioral factors to biochemical 
and molecular assessments of mitochondrial content and function. (B) Schematic of the internal components 
of the mitochondrial respiratory chain (complexes I-V), the tricarboxylic acid (TCA, also Krebs) cycle, 
and the mitochondrial genome (mtDNA). Enzymatic activities measured include citrate synthase (CS), 
succinate dehydrogenase (SDH, complex II), and cytochrome c oxidase (COX, complex IV). mtDNA copy 
number (mtDNAcn) was measured using qPCR. Using this data, the Mitochondrial Health Index (MHI) was 
calculated for each patient with mean-centered activities of respiratory chain complexes, divided by markers 
of mitochondrial  content3. (C) Enzymatic activities for CS, SDH, and COX, (D) mtDNAcn, and (E) MHI. (F) 
Average COX/SDH ratio and (G) scatterplot illustrating the distinct mitochondrial phenotypes between benign 
vs EOC. Each data-point represents the average of two measures for a participant; graphed on Log10 scale. 
n = 51 benign, n = 128 high-grade EOCs, P values from one-way ANOVA performed on log-transformed data. 
*** p < 0.001. The non-transformed data is shown.
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genome density (mtDNA/CS) per mitochondrion is dramatically reduced in tumors. Together, these findings 
demonstrate that beyond gross changes in mitochondrial abundance, tumor mitochondria exhibit abnormal 
mitochondrial phenotypes that are qualitatively different from benign tissue.
Mitochondrial content and function across tumor stages and types. Overall, EOC presented 
with a broad range of mitochondrial enzymatic activities and mtDNAcn (Fig. 3A-B). Average respiratory chain 
enzyme activities were approximately equivalent in Stages I through III and then decreased substantially by 
Stage IV. For CS, SDH, and COX, metastatic tumors (Stage IV) showed approximately half (55.8–61.9%) the 
enzymatic levels of stage I tumors, although these differences were non-significant (p values > 0.05) due to high 
variation within each stage. mtDNAcn of Stage IV tumors was on average 28.2% lower than in Stage I tumors, or 
half of the magnitude of differences between stages I and IV observed for enzymatic activities) (Fig. 3C), again 
suggesting that mtDNAcn may be regulated independently from enzymatic components. The MHI did not differ 
statistically across stages (Fig. 3D).
Next, we compared mitochondrial measures across several EOC histological subtypes. This revealed two main 
points: (1) there is large inter-individual variation in enzymatic activities even within the same tumor type; and 
(2) there are potentially large differences in activities between tumor histologies (Fig. 3E-G), although this study 
was not powered to detect these differences.
Tumor mitochondrial parameters and IL‑6. Mitochondrial function is linked to pro-inflammatory 
signaling and cytokine production, including interleukin 6 (IL-6)30,31 and IL-6 signaling may influence tumor-
promoting processes such as  angiogenesis32. Therefore, to evaluate whether mitochondrial measures are related 
to the pro-inflammatory phenotype, we measured IL-6 levels in ascites and plasma from participants with EOC, 
across all stages, and systematically tested their association with tumor mitochondrial respiratory chain enzy-
matic activities and mtDNAcn (Fig. 4A). Tumor mitochondrial respiratory chain activity and content, particu-
larly the integrated metric MHI (Fig.  4B), were consistently negatively correlated with IL-6 levels in ascites 
(p values = 0.042 to < 0.001); moreover correlations were up to an order of magnitude larger in ascites than in 
plasma. In contrast, mtDNA density per mitochondrial unit (ratio of mtDNAcn/CS) was correlated positively 
with ascites IL-6 (p value = 0.014) (Fig.  4C), possibly reflecting the pro-inflammatory intracellular signaling 
effects of  mtDNA33,34.
Associations between biobehavioral factors and mitochondrial phenotypes. Because serous 
tumors are the predominant tumor type in ovarian cancer, we focused analyses with biobehavioral factors on 
high-grade serous EOC. These exploratory analyses examined whether mitochondrial parameters were associ-
ated with negative and positive biobehavioral factors. Negative biobehavioral factors were moderately inter-
correlated, sharing between 14.9 and 51.9% of their variance, and the proportion of shared variance among 
positive biobehavioral factors ranged from 0.003 to 42.1%, indicating no co-linearity to moderate co-linearity 
between these variables. The strength and direction of each mitochondria-biobehavioral correlation is displayed 
as a heat map in Fig. 5A and with 95% confidence intervals shown for the enzymatic mitochondrial measures 
Figure 3.  Mitochondrial phenotyping across EOC histologic subtypes and benign tissue. (A) EOC histologic 
subtypes included in this study. (B) Mitochondrial enzymatic activities, (C) mtDNAcn, and (D) MHI by tumor 
stage. Data are means ± SEM. (E) Enzymatic activities, (F) mtDNAcn, and (G) MHI values by EOC histologic 
subtype shown as violin plots with each datapoint representing an individual patient. P values from one-way 
ANOVA performed on log-transformed data. The non-transformed data is shown.
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(CS, SDH, COX) in Fig. 5B. These results suggest patterns of association with relatively small to moderate effect 
sizes (range: r = − 0.43 to 0.47) across multiple mitochondrial measures and biobehavioral assessments, leading 
to three main observations.
First, in benign tissues, negative biobehavioral measures such as depression, fatigue, and negative mood 
tended to be generally associated with lower levels of mitochondrial enzymatic activities. Fatigue was the measure 
most consistently related to mitochondrial activity, with effect sizes in the moderate range for all mitochondrial 
enzymes, and significant negative associations with COX r = − 0.38, p = 0.04 and MHI r = − 0.40, p = 0.039 and 
positive associations with mtDNA/CS r = 0.37, p = 0.059. In contrast, positive biobehavioral measures such as 
vigor, well-being, and positive mood tended to be positively correlated with mitochondrial parameters, although 
only the relationship between social attachment and COX reached statistical significance, r = 0.47, p = 0.004. 
Although these relationships were not generally statistically significant due to the small sample size in many 
of these analyses (n = 27–36), we note an apparent consistency in their direction across primary mitochondrial 
measures (CS, SDH, COX). This would seem to be consistent with previous findings in blood  leukocytes22, and 
these observations should be examined further in more strongly powered studies.
Second, in benign tissue, compared to the associations seen in respiratory chain enzymes, associations 
between biobehavioral factors and mtDNAcn appear to be in directions opposite to those noted above. This 
would be consistent with the existence of independent mechanisms linking biobehavioral factors to mtDNAcn 
and respiratory chain function.
Third, in contrast to the apparent biobehavioral-mitochondrial associations in benign tissue, these associa-
tions in high grade serous EOC tended to be smaller in magnitude (see Fig. 5B). In EOC, contrary to expectation, 
both positive and negative factors were associated with higher levels of respiratory chain enzymes (depressive 
mood and COX: r = 0.26, p = 0.014; quality of life and SDH (r = 0.29, p = 0.009); well-being and SDH (r = 0.28, 
p = 0.050). Interestingly, biobehavioral characteristics indicating positive affect (Center for Epidemiologic Stud-
ies Depression Scale-positive subscale [CESD-positive], Profile of Mood States vigor subscale [POMS-vigor]), 
which may be more fleeting, were not strongly associated with respiratory chain enzymes. In contrast, the posi-
tive dimensions of quality of life and well-being which may reflect a more sustained positive orientation, were 
significantly associated with higher levels of respiratory chain activity in tumor tissue.
Discussion
In this study of epithelial ovarian cancer, we examined multiple enzymatic and molecular mitochondrial meas-
ures, and the intersection of mitochondrial biology and biobehavioral factors. After interrogating mitochondrial 
gene expression from a large database of ovarian cancer survival as proof-of-concept of the significance of 
mitochondria in ovarian tumor biology, we leveraged a high-throughput mitochondrial phenotyping platform 
to measure markers of mitochondrial content and function. In parallel, to investigate whether mitochondrial 
remodeling represents a potential pathway by which biobehavioral processes may support tumor growth and 
progression, we analyzed several domains of psychosocial functioning in ovarian cancer patients at the time of 
surgery. From a tumor biology perspective, our mitochondrial respiratory chain and mtDNA results demonstrate 
striking differences in mitochondrial phenotypes between tumor and benign tissues, and suggest potential dif-
ferences among different histologies and tumor stages. Our exploratory analyses also suggest relatively blunted 
associations between biobehavioral factors and mitochondria in high grade serous EOC, in comparison with 
benign tissue where positive and negative biobehavioral measures are potentially more strongly related to mito-
chondrial function. This is the first study to examine the association of biobehavioral factors with mitochon-
drial content and function in cancer. Overall, these findings extend pre-clinical work suggesting mitochondrial 
reprogramming in ovarian cancer in humans.
The extension of pre-clinical findings concerning the influence of MPC2 on mitochondrial metabolism and 
tumor  growth27 to MPC2 gene expression and survival in women with EOC provides proof-of-concept that 
mitochondrial (dys)function may contribute to clinical outcomes. In systematically broadening the search to 
other mitochondrial components, one of the striking observations from the gene expression-survival analysis 
Figure 4.  Mitochondrial measures and IL-6 in high-grade epithelial ovarian carcinoma. (A) Pearson 
correlations between mitochondrial measures and IL-6 levels measured in ascites and plasma. Note the similar 
patterns of correlation between ascites and plasma, and the contrast in the associations between mtDNA-related 
measures (positive) and primary measures of mitochondrial content and respiratory chain function (negative). 
(B) Scatterplots of the correlations between ascites IL-6 levels and the mitochondrial health index (MHI), and 
(C) mtDNA density per mitochondrion (mtDNAcn/CS). n = 50–64 for ascites, 82–110 for plasma.
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Figure 5.  Associations of biobehavioral factors with mitochondrial content and function in high-grade serous 
epithelial ovarian carcinoma (EOC) and in epithelial and stromal benign tissues. (A) Correlations between 
negative/positive biobehavioral factors and markers of mitochondrial content (CS, mtDNAcn), mitochondrial 
respiratory chain enzymatic activities (SDH, COX), and mtDNAcn density (mtDNAcn/CS). Results are Pearson 
correlation coefficients illustrated in a heatmap, generated through Prism 8 (Graphpad), depicting the direction 
(color) and strength (saturation) of the associations. Benign and high-grade serous EOC tissues may have 
opposite associations among biobehavioral factors and mitochondrial activity particularly for CS and respiratory 
chain complexes II (SDH) and IV (COX). Center for Epidemiologic Studies Depression Scale (CESD); 
Profile of Mood States (POMS); Social Provisions Scale (SPS), Functional Assessment of Cancer Therapies-
General (FACT-G) (B) Effect sizes shown in A for the primary enzymatic measures (CS, SDH, COX) with 
95% confidence intervals. Whereas data from subscales and scales are presented in A, overlapping scales and 
subscales are omitted from this panel. Correlation coefficients determined from log-transformed data. n = 22–36 
benign, n = 37–91 EOC; correlations are Pearson r from log-transformed values.
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(Fig. 1) is the heterogeneity in the direction of the associations for proteins belonging to the same complex. To 
our knowledge, this has not previously been examined in detail. For example, higher expression of NDUFAF2 
was associated with lower mortality. NDUFAF2 is a complex I assembly factor that is required for synthesizing 
the part of complex I that protrudes in the mitochondrial matrix and binds NADH (N module) produced by the 
Krebs cycle. Paradoxically, we find that an elevated expression of many of the structural complex I subunits that 
are part of the N module is associated with higher mortality. This may be due to the fact that when such subunits 
are overexpressed in the absence of a concomitant overexpression of NDUFAF2, they interact with other proteins 
to disrupt other signaling networks. For instance, NDUFV1 interacts with  LRRK235, and NDUFS1 interacts with 
the iron-sulfur cluster co-chaperone protein  HscB36; hence it is conceivable that when overexpressed they bind 
and sequester HscB to the point that other cellular processes dependent on iron-sulfur clusters are compromised. 
Similarly, NDUFS6 interacts with BOLA3, which also regulates iron-sulfur cluster  biogenesis37 while NDUFS4 
interacts with proline-rich transmembrane protein 2 (PRRT2)38. In relation to mtDNA, higher expression of 
both isoforms of ATAD3 (ATAD3A and ATAD3B), which are likely involved in cholesterol metabolism in addi-
tion to mtDNA nucleoid  regulation39, is associated with > 50% increase in mortality. In contrast, expression 
of both TFAM and the mitochondrial RNA polymerase, which both promote mtDNA gene  expression40, are 
negatively associated with mortality. Thus, as expected from known protein–protein interactions, these data also 
demonstrate that different respiratory chain subunits belonging to the same protein complexes could have vastly 
different influence on tumor biology depending upon their specific molecular interactions and position within 
multi-protein respiratory chain complexes.
One point of interest relates to mitochondrial content (CS and mtDNAcn) which was found to be excep-
tionally high in EOC relative to benign tissue. While some studies have reported a decrease in SDH and COX 
activity in breast and renal  carcinomas42, we report increased activity in EOC compared to healthy tissue. CS 
upregulation has been observed in other ovarian cancer  studies41. In cancer cells, mitochondria are biosynthetic 
centers—several aspects of their function, including the respiratory chain and associated Krebs cycle enzymes, 
are diverted to provide biosynthetic products to support cell  growth6,43 (reviewed  in44). The upregulation of 
CS might be responsible for regulating citrate levels and affecting cellular lipid synthesis, which drives key 
cellular processes such as transformation, tumor development, and disease  progression45. Citrate, like other 
mitochondria-derived metabolites with pro-oncogenic  effects46, is considered an  oncometabolite42. Other known 
mitochondrial metabolites accumulated in tumors can also activate oncogenic signaling cascades, including 
succinate and fumarate that are the substrate and product, respectively, of the reaction catalyzed by  SDH46,47,. 
As increased CS and SDH activity would result in an increase in citrate and fumarate, our findings indicating a 
significant increase in CS and SDH activities in tumor compared to benign mitochondria suggest that this may 
be worth examining in future studies. More generally, increased mitochondrial mass could be the product of 
increased biogenesis, decreased autophagic removal of mitochondria, or a combination of these and other fac-
tors. In support of this point, mitochondrial biogenesis has been observed in various human tumor types and 
correlates with metastatic  behavior48 and poor clinical  outcomes2.
Another unresolved point relates to the association between mitochondrial content and function with IL-6. 
Besides abnormal mitochondrial metabolism, inflammation is another biological hallmark of tumor trans-
formation and  progression49. In patients with EOC, we noted a negative association between mitochondrial 
enzyme activities and IL-6 levels in ascites. In circulating blood, these associations were in the same direction as 
ascites but less robust, consistent with the tumors being the primary source of IL-650 and the “leakage” of IL-6 
into circulation. Our data suggest a fairly robust negative association between both mitochondrial mass and 
respiratory chain function and IL-6. This apparent anti-inflammatory phenotype of mitochondria-rich tissues 
could be explained by a number of mechanisms that require further work to confirm. One possibility is that this 
association reflects some crosstalk between tumor mitochondria and resident immune  cells51,52. Consistent with 
our data, the upregulation of mitochondrial biogenesis (higher mitochondrial mass, respiratory chain activity) 
promotes an anti-inflammatory shift in  monocytes53. Acute perturbations of mitochondrial respiratory chain 
function also alter cytokine production in human  leukocytes54, substantiating the link between mitochondrial 
function and cytokine production in human immune cells. Together, these data suggest that the mitochondrial 
phenotype may influence the inflammatory state, rather than the other way around. However, further work is 
needed to test this proposition in EOC.
There is a need to establish biologically plausible pathways linking psychosocial experiences with human 
health  outcomes55. Here, the exploratory associations between biobehavioral and mitochondrial measures sug-
gest that compared to benign tissue, EOC may respond differently to negative psychosocial factors. Benign tissue 
appeared to have similar associations to those we have previously reported in leukocytes in response to positive 
and negative biobehavioral  factors22. Specifically, in our previous work, positive mood (more so than negative 
mood) was significantly associated with future mitochondrial respiratory chain function (i.e., MHI)22. While the 
basis for any such difference remains unclear, we speculate that abnormal mitochondrial phenotypes in tumors 
may render tumor mitochondria less responsive to the natural influence of neuroendocrine factors believed to 
mediate the effects of psychosocial factors in other cell  types12. However, on the basis of small effect sizes that are 
largely not statistically significant, we hesitate to draw definite conclusions, and we advocate for further, more 
adequately-powered studies to examine this question.
Contrary to observations involving mitochondrial content and respiratory chain activity, mitochondrial 
genome abundance (mtDNAcn), particularly when expressed as mtDNA density per mitochondrion (relative to 
mitochondrial mass, mtDNAcn/CS), was found to be positively correlated with ascites IL-6 levels. This antago-
nistic association of mitochondrial respiratory chain components and mtDNAcn with IL-6 is similar to our 
findings with biobehavioral factors. Interestingly, mtDNA instability can cause its release in the cytoplasm and 
extracellular space where it is potentially recognized as foreign (i.e., bacterial) by innate immune response sys-
tems, triggering the production of antiviral and pro-inflammatory  cytokines56,57. Although it was not possible 
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to measure levels of cf-mtDNA in the current study, our data suggest that mtDNA signaling could, in ovarian 
cancer, have pro-inflammatory effects. The origin of this opposite association between respiratory chain com-
ponents and mtDNAcn with both inflammation and biobehavioral outcomes remains unclear but emphasizes 
the notion that respiratory chain function and mtDNAcn are not equivalent markers of mitochondrial function.
Overall, our results demonstrate abnormal mitochondrial phenotypes in ovarian tumors and open new 
questions related to the role of mitochondrial biology in EOC, including tumor sensitivity to biobehavioral 
factors. As mitochondrial dysfunction is directly implicated in several chemoresistance  pathways7, future work 
may also examine how altered mitochondrial functioning may contribute to clinically relevant processes such 
as chemoresistance and clinical outcomes.
Methods
Publicly available ovarian cancer gene expression dataset. To examine the association between 
tumor gene expression and progression-free survival, we queried Kaplan Meier Plotter (http:// kmplot. com) to 
compute the survival over time in 1435 ovarian cancer patients. Kaplan Meier Plotter is the largest publicly avail-
able dataset of microarray-based gene expression in 21 different cancer types, including ovarian cancer. Analyses 
were not restricted to different subtypes (histology, stage, grade, TP53 mutation) or to treatment groups (debulk, 
chemotherapy). We analyzed the prognostic value of transcript level for genes encoding mitochondrial res-
piratory chain subunits of complexes I through V, as well as genes related to mtDNA maintenance and stability. 
Patients were divided into two groups of high and low gene expression using default settings to establish the 
optimal threshold as a cutoff. The two groups were compared on progression-free survival over follow up peri-
ods of up to 20.8 years. To obtain an unambiguous expression estimate for each gene, the optimal probe selected 
based on the JetSet  algorithm58 was selected to represent each gene. A survival plot was then generated for 
each gene with sample sizes varying according to the gene data available (n = 614–1435 for each gene). The KM 
survival estimates and log-rank tests statistic were used to determine the hazard ratio, 95% CI and p-value for 
each gene, and the data plotted as forest plots to visualize the direction and magnitude of associations between 
complex-specific genes and progression-free survival. To obtain an estimate of false discovery rate in this data-
set, we randomly selected 200 genes (“null set”) out of the total 15,000 available human genes. We obtained the 
hazard ratios and 95% confidence interval for each random gene and computed the proportion of significant 
genes with these parameters, which serves as a reference to evaluate the proportion of significant genes in each 
mitochondrial respiratory chain complexes and mtDNA-related genes. Sensitivity analyses restricting the data to 
high grade patients (KMPlotter grades 2 and 3) were then conducted on MPC2 and Complex II- and mtDNA-
associated genes which showed > 70% significant associations with survival compared to the null set.
Clinical data. Participants were part of a larger study of biobehavioral factors and tumor progression in 
ovarian cancer who were prospectively recruited at an initial clinic visit pre-surgery/treatment initiation at 2 
large Midwestern hospitals between 12/03 and 8/14. All procedures were IRB approved and all participants 
signed informed consents. All human subjects were approved by the Institutional Review Boards at the Univer-
sity of Iowa and Washington University and all research was performed in accordance with relevant guidelines 
and regulations.
Inclusion/exclusion. Participants over 18 years old with a newly-diagnosed, histologically-confirmed, primary 
invasive epithelial ovarian, peritoneal, or fallopian tube carcinoma or a tumor suspected for ovarian cancer 
which turned out to be benign were eligible for inclusion in the parent study. Primary cancers of another organ, 
non-epithelial ovarian tumors, tumors of low malignant potential, previous cancer, use of systemic steroid medi-
cation in the last 4 months, or comorbidities known to influence the immune response were excluded. For the 
current analyses, only high grade ovarian tumor tissue was included, and benign tissue was restricted to epithe-
lial (e.g. cystadenoma) and stromal (e.g. fibroma) histology.
Procedures. Psychosocial assessments were completed at home prior to surgery or initiation of treatment and 
clinical data was obtained from medical records. Tissue samples were obtained from primary surgeries con-
ducted prior to beginning of treatment and were flash frozen in liquid nitrogen immediately upon acquisition. 
Tissue was available from 128 patients subsequently diagnosed with high-grade EOC and from 51 patients with 
benign epithelial or stromal pelvic masses. Plasma was obtained immediately prior to surgery and ascites was 
obtained from surgery. Both were frozen at -80 °C until analysis.
Psychosocial measures. The Center for Epidemiological Studies Depression Scale (CESD) contains 20 
items assessing frequency of depressive symptoms over the past  week59,60. Scores of 16 or higher are indicative 
of clinical depression. Four validated subscales have been described and associated with physiological variables 
in previous ovarian cancer  research59,60. In this study, we used the total score, and the depressed mood, positive 
mood, and vegetative subscales.
The Profile of Mood States short form (POMS) includes 37 adjectives describing mood over the last month. 
Six factors are included in this measure: anxiety, dysphoria, anger, vigor, fatigue, and confusion. A total distress 
score (total mood disturbance: TMD) is derived from the sum of the 5 negative mood factors minus the vigor 
subscale. The POMS short form is well-validated, has strong psychometric properties, and is commonly used 
for assessment of distress in cancer  populations61. Here, in addition to the total scale, we used the fatigue and 
vigor scales as ways of examining energy/vitality levels that might be associated with mitochondrial activity.
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The Social Provisions Scale (SPS) is a 24-item self-report scale measuring an individual’s perceptions of their 
social  support62. Here we use the attachment subscale which has shown strong associations with physiological 
measures in previous studies of female cancer  patients63.
The Psychological Well-Being Scale measures perceived psychological well-being64. We administered 4 of 
the 6 subscales (purpose in life, environmental mastery, personal growth, and self-acceptance) thought to be 
particularly relevant for individuals with chronic health challenges. We used the 7-item version of the scales, 
with higher scores indicating greater well-being.
The Functional Assessment of Cancer Therapy (FACT-G) is a well-validated and psychometrically sound 
27-item scale assessing 4 facets of quality of life (physical, emotional, functional, and social well-being) experi-
enced by cancer patients during the previous week. Higher scores indicate better quality of  life65.
Mitochondrial content and function. Tissue preparation. Tissue samples were flash frozen and stored 
in liquid nitrogen until processing. For each sample, two partitions of 50–65 mg were cut with a scalpel on 
a clean, cooled surface. The partitions were allowed to thaw and were mechanically minced on ice. Minced 
samples were placed on dry ice and stored at − 80 °C until homogenization in batches. To account for potential 
tumor heterogeneity, enzymatic activities and mtDNAcn were measures on each partition individually and the 
average of both partitions was calculated, producing a single, more stable value for each tumor and benign sam-
ple. Pre-cut tissue samples were mechanically homogenized with Tungsten beads (Cat #69,997) in homogeniza-
tion buffer containing 1 mM EDTA and 50 mM triethanolamine (pH 7.4) 1:20 (1 mg/20 µl), using a robotized 
TissueLyser II (Qiagen) with a 1-min run (30 cycles/sec) followed by an incubation on ice for 5 min, repeated for 
a total of three runs. Samples were vortexed before each assay to ensure homogeneity.
Mitochondrial enzymatic activity assays. Mitochondria enzyme activities were quantified spectrophotometri-
cally for citrate synthase (CS), cytochrome c oxidase (COX, complex IV), succinate dehydrogenase (SDH, com-
plex II), and NADH dehydrogenase (complex I). For each assay, 20 ul of homogenate was added per reaction. All 
assays were performed at 30 °C. Citrate synthase (CS) activity was measured by detecting the increase in absorb-
ance at 412 nm, in a reaction buffer (200 mM Tris, pH 7.4) containing acetyl-CoA 0.2 mM, 0.2 mM 5,5′-dith-
iobis-(2-nitrobenzoic acid) (DTNB), 0.55 mM oxaloacetic acid, and 0.1% Triton X-100. Final CS activity was 
obtained by integrating  OD412 change from 120 to 300 s, and by subtracting the non-specific activity measured in 
the absence of oxaloacetate. Cytochrome c oxidase (COX, or complex IV) activity was measured by detecting the 
decrease in absorbance at 550 nm at 30 °C, in a 100 mM potassium phosphate reaction buffer (pH 7.5) contain-
ing 0.1% n-dodecylmaltoside and 100uM of purified reduced cytochrome c. Final COX activity was obtained 
by integrating  OD550 change over 100–350 s and by subtracting spontaneous cyt c oxidation without cell lysate. 
Succinate dehydrogenase (SDH, or complex II) activity was measured by detecting the decrease in absorbance at 
600 nm at 30 °C, in potassium phosphate 100 mM reaction buffer (pH 7.5) containing 2 mM EDTA, 1 mg/ml 
bovine serum albumin (BSA), 4 μM rotenone, 10 mM succinate, 0.25 mM potassium cyanide, 100 μM decy-
lubiquinone, 100 μM DCIP, 200 μM ATP, 0.4 μM antimycin A. Final SDH activity was obtained by integrating 
 OD600 change over 200–600 s and by subtracting activity detected in the presence of malonate (5 mM), a specific 
inhibitor of SDH. NADH dehydrogenase (complex I) activity was measured by detecting the decrease in absorb-
ance at 600 nm at 37 °C, in potassium phosphate 100 mM reaction buffer (pH 7.5) containing 2 mM EDTA, 3.5 
mg/ml bovine serum albumin (BSA), 0.25 mM potassium cyanide, 100 μM decylubiquinone, 100 μM DCIP, 
200 μM NADH, 0.4 μM antimycin A. Final complex I activity was obtained by integrating  OD600 change over 
200–440 s and by subtracting activity detected in the presence of rotenone (500 μM) and piericidin A (200 μM), 
specific inhibitors of complex I. Activities for complex I were too low and were not used for analyses. The molar 
extinction coefficients used were 13.6 L  mol-1  cm-1 for DTNB, 29.5 L  mol−1  cm−1 for reduced cytochrome c, and 
16.3 L  mol−1  cm-1 for DCIP. Samples were lysed for 10 h at 55 °C, followed by inactivation at 95 °C for 10 min. 
The lysate was directly used as template DNA for measurements of mtDNA copy number.
mtDNA copy number. The same homogenate used for enzymatic measurements (10ul) was lysed in lysis buffer 
containing 100 mM Tris HCl pH 8.5, 0.5% Tween 20, and 200ug/ml proteinase K (10 h at 55 °C, and used directly 
for qPCR-based measurements of mtDNA copy number. qPCR reactions were setup in triplicates using a liquid 
handling station (ep-Motion5073, Eppendorf) in 384 well qPCR plates. Duplex qPCR reactions with Taqman 
chemistry were used to simultaneously quantify mitochondrial and nuclear amplicons in the same reactions. 
Master  Mix1 for ND1 (mtDNA) and B2M (nDNA) included: TaqMan Universal Master mix fast (life technolo-
gies #4,444,964), 300 nM of custom design primers and 100 nM probes (ND1-Fwd: GAG CGA TGG TGA GAG 
CTA AGGT, ND1-Rev:CCC TAA AAC CCG CCA CAT CT,Probe: HEX-CCA TCA CCC TCT ACA TCA CCG CCC 
-3IABkFQ.B2M-Fwd: CCA GCA GAG AAT GGA AAG TCAA, B2M-Rev: TCT CTC TCC ATT CTT CAG TAA GTC 
AACT, Probe: FAM-ATG TGT CTG GGT TTC ATC CAT CCG ACA-3IABkFQ). Master  Mix2 for COX1 (mtDNA) 
and RNaseP (nDNA) included : TaqMan Universal Master Mix fast, 300 nM of custom design primers and 100 
nM probes (COX1-Fwd: CTA GCA GGT GTC TCC TCT ATCT, COX1-Rev: GAG AAG TAG GAC TGC TGT GAT 
TAG , Probe: FAM-TGC CAT AAC CCA ATA CCA AAC GCC -3IABkFQ. RnaseP-Fwd: AGA TTT GGA CCT GCG 
AGC G, RNaseP-Rev: GAG CGG CTG TCT CCA CAA GT, Probe: FAM-TTC TGA CCT GAA GGC TCT GCGCG-
3IABkFQ. The samples were then cycled in a QuantStudio 7 flex qPCR instrument (Applied Biosystems) at 50 
°C for 2 min, 95 °C for 20 s, 95 °C for 1 min, 60 °C for 20 s for 40 × cycles. Reaction volumes were 20ul. To ensure 
comparable Ct values across plates and assays, thresholds for fluorescence detection for both mitochondrial and 
nuclear amplicons were set to 0.08.
mtDNAcn was calculated using the ΔCt method. The ΔCt was obtained by subtracting the average mtDNA 
Ct values from the average nDNA Ct values. Relative mitochondrial DNA copies are calculated by raising 2 to 
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the power of the ΔCt and then multiplying by 2 to account for the diploid nature of the nuclear genome. The 
number of mtDNAcn =  2ΔCt × 2. Both ND1 and COX1 yielded highly correlated results and the average of both 
amplicon pairs was used as mtDNAcn value for each sample.
Statistical analyses. The hazard ratios (HR) and 95% confidence for survival differences between high- 
and low-expression tumors was obtained from http:// kmplot. com. Statistical Package for the Social Sciences 
(SPSS) version 25.0 and R version 3.6.3 were used to analyze all other data. All distributions were examined for 
outliers and nonnormality. Log transformations were applied to normalize distributions where necessary. Mito-
chondrial markers were compared between benign and tumor data using analyses of variance (ANOVAs). ANO-
VAs were also used to examine overall differences in means of mitochondrial variables according to cancer stage 
or histology. Pearson product moment correlations were calculated to assess relationships between psychosocial 
variables and mitochondrial variables and between mitochondrial variables and IL-6. A 95% confidence interval 
was generated for each correlation coefficient. Heatmaps were generated using Prism 8 (Graphpad) https:// www. 
graph pad. com/ scien tific- softw are/ prism/.
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